Gene therapy for vascular disease

Annals of Vascular Surgery

Volumn 11, Issue 2, 1997, Pages 189-199

  Schwartz, Lewis B M ^a   Moawad, John ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BRAIN ISCHEMIA; GENE THERAPY; HEART MUSCLE ISCHEMIA; HUMAN; INTESTINE ISCHEMIA; MUSCLE ISCHEMIA; PRIORITY JOURNAL; REVIEW;

EID: 0030976001     PISSN: 08905096     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100169900034     Document Type: Article

References (100)

1. Mendel GJ. Versuche über Pflanzen-Hybriden. Verh Neturf Vereins Brünn 1866;4:3-47.
2. Avery OT, MacLeod CM, McCarty M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types. J Exp Med 1944;79:137-158.
3. Watson JD, Crick FHC. Genetical implications of the structure of deoxyribonucleic acid. Nature 1953;171:964-969.
4. Wolff JA, Lederberg J. An early history of gene therapy. Human Gene Therapy 1994;5:469-480.
5. Jackson DA, Symons R, Berg P. Biochemical method for inserting new genetic information into DNA of simian virus 40: Circular SV40 DNA molecules containing Lambda phage genes and the galactose operon of Escherichia coli. Proc Natl Acad Sci USA 1972;69:2904-2909.
6. Chien KR, Knowlton KU. Cardiovascular molecular biology: Introduction to the series. Circ 1989;80(2):219-233.
7. Nicolau C, LePape A, Soriano P, et al. In vivo expression of rat insulin after intravenous administration of the liposome-entrapped gene for rat insulin I. Proc Natl Acad Sci USA 1983;80:1068-1072.
8. Nabel EG, Plautz G, Boyce FM, et al. Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science 1989;244:1342-1344.
9. Blaese RM, Culver KW, Miller AD, et al. T lymphocytedirected gene therapy for ADA-SCID: Initial trial results after 4 years. Science 1995;270:475-480.
10. Isner JM, Walsh K, Rosenfield K, et al. Arterial gene therapy for restenosis. Human Gene Therapy 1996;7:989-1011.
11. Marshall E. Gene therapy's growing pains. Science 1995; 269:1050-1055.
12. Lyerly HK, DiMaio JM. Gene delivery systems in surgery. Arch Surg 1993;128:1197-1206.
13. Nabel EG. Gene therapy for cardiovascular disease. Circ 1995:91:541-548.
14. Nabel EG, Pompili VJ, Plautz GE, Nabel GJ. Gene transfer and vascular disease. Cardiovasc Res 1994;28:445-455.
15. Finkel T, Epstein SE. Gene therapy for vascular disease. FASEB J 1995:9:843-851.
16. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Bio Techniques 1989;7:980-990.
17. Kozarsky KF, Wilson JM. Gene therapy: adenovirus vectors. Curr Opin Gen Devel 1993;3:499-503.
18. Kay M. Adenoviral vectors: Promises and pitfalls. J Vasc Surg 1996:24:160-161.
19. Newman KD, Dunn PF, Owens JW, et al. Adenovirusmediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest 1995;96:2955-2965.
20. Lim CS, Chapman GD, Gammon RS, et al. Direct in vivo gene transfer into the coronary and peripheral vasculatures of the intact dog. Circ 1991;83:2007-2011.
21. Nabel EG, Plautz G, Nabel GJ. Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science 1990;249:1285-1288.
22. Dichek DA, Neville RF, Zwiebel JA, et al. Seeding of intravascular stents with genetically engineered endothelial cells. Circ 1989;80:1347-1353.
23. Swain JL. Gene therapy: A new approach to the treatment of cardiovascular disease. Circ 1989;80(5):1495-1496.
24. Lemarchand P, Jones M, Yamada I, Crystal RG. In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ Res 1993;72:1132-1138.
25. Rome JJ, Shayani V, Newman KD, et al. Adenoviral vectormediated gene transfer into sheep arteries using a doubleballoon catheter. Human Gene Therapy 1994;5:1249-1258.
26. Steg PG, Feldman LJ, Scoazec J, et al. Arterial gene transfer to rabbit endothelial and smooth muscle cells using percutaneous delivery of an adenoviral vector. Circ 1994;90: 1648-1656.
27. Willard JE, Landau C, Glamann B, et al. Genetic modification of the vessel wall: Comparison of surgical and catheter-based techniques for delivery of recombinant adenovirus. Circ 1994;89:2190-2197.
28. Chapman GD, Lim CS, Gammon RS, et al. Gene transfer into coronary arteries of intact animals with a percutaneous balloon catheter. Circ Res 1992;71:27-33.
29. Wilson JM, Birinyi LK, Salomon RN, et al. Implantation of vascular grafts lined with genetically modified endothelial cells. Science 1989;244:1344-1346.
30. Hong-zhi B, Yoshiki S, Tomoyuki Y, et al. Gene transfer of senescent cell-derived inhibitor 1 into vein graft inhibited neointimal hyperplasia in vivo associated with induction of smooth muscle cell redifferentiation. Circ 1995;92(suppl I):I-642.
31. Chen S, Wilson JM, Muller DWM. Adenovirus-mediated gene transfer of soluble vascular cell adhesion molecule to porcine interposition vein grafts. Circ 1994;89:1922-1928.
32. Kupfer JM, Ruan XM, Liu G, et al. High-efficiency gene transfer to autologous rabbit jugular vein grafts using adenovirus-transferrin/polylysine-DNA complexes. Human Gene Therapy 1994;5:1437-1443.
33. Dunn PF, Newman KD, Jones M, et al. Seeding of vascular grafts with genetically modified endothelial cells: Secretion of recombinant tPA results in decreased seeded cell retention in vitro and in vivo. Circ 1996;1439-1446.
34. Golden MA. Modification of vein graft adaptation using adenoviral vectors. J Vasc Surg 1996;24:161-163.
35. Califf RM, Fortin DF, Fried DJ, et al. Restenosis after coronary angioplasty: An overview. J Am Coll Card 1991;17: 2B-13B.
36. Erickson CA, Towne JB, Seabrook GR, et al. Ongoing vascular laboratory surveillance is essential to maximize long-term in situ saphenous vein bypass patency. J Vasc Surg 1996;23:18-27.
37. Gray BH, Sullivan TM, Young JR, Olin J. High incidence of restenosis/reocclusion of intravascular stents in the percutaneous treatment for long segment superficial femoral artery atherosclerotic disease. Soc Vas Surg 1996(50):66.
38. Libby P, Schwartz D, Brogi E, et al. A cascade model for restenosis: A special case of atherosclerosis progression. Circ 1992;86[suppl III]:III-47-III-52.
39. Liu MW, Roubin GS, King SB, III. Restenosis after coronary angioplasty: Potential biologic determinants and role of intimai hyperplasia. Circ 1989;79(6):1374-1387.
40. Schwartz SM, deBlois D, O'Brien ERM. The intima: soil for atherosclerosis and restenosis. Circ Res 1995;77:445-465.
41. Bennett MR, Schwartz SM. Antisense therapy for angioplasty restenosis: Some critical considerations. Circ 1995; 92:1981-1993.
42. Mintz GS, Popma JJ, Pichard AD, et al. Arterial remodeling after coronary angioplasty: A serial intravascular ultrasound study. Circ 1996(94):35-43.
43. Schwartz RS, Holmes DR, Jr., Topol EJ. The restenosis paradigm revisited: An alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992;20:1284-1293.
44. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after injury: I. Smooth muscle growth in the absence of endothelium. Lab Invest 1983;49:327-333.
45. Wang CY, Petryniak B, Thompson CB, et al. Regulation of the Ets-related transcription factor Elf-1 by binding to the retinoblastoma protein. Science 1993;260:1330-1335.
46. Hollingsworth RE, Jr., Hensey CE, Lee WH. Retinoblastoma protein and the cell cycle. Curr Opin Genet Dev 1993; 3:55-62.
47. Chen PL, Scully P, Shew JY, et al. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 1989;58:1193-1198.
48. Ohno T, Gordon D, San H, et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994;265:781-784.
49. Guzman RJ, Lemarchand P, Crystal RG, et al. Efficient and selective adenovirus-mediated gene transfer into vascular neointima. Circ 1993;88:2838-2848.
50. Plautz G, Nabel EG, Nabel GJ. Introduction of vascular smooth muscle cells expressing recombinant genes in vivo. Circ 1991;83:578-583.
51. Lee SW, Trapnell BC, Rade JJ, et al. In vivo adenoviral vector-mediated gene transfer into balloon-injured rat carotid arteries. Circ Res 1993;73:797-807.
52. Riessen R, Rahimizadeh H, Blessing E, et al. Arterial gene transfer using pure DNA applied directly to a hydrogelcoated angioplasty balloon. Human Gene Therapy 1993;4: 749-758.
53. Leclerc G, Gal D, Takeshita S, et al. Percutaneous arterial gene transfer in a rabbit model. J Clin Invest 1992;90:936-944.
54. French BA, Mazur W, Ali NM, et al. Percutaneous transluminal in vivo gene transfer by recombinant adenovirus in normal porcine coronary arteries, atherosclerotic arteries, and two models of restenosis. Circ 1994;90:2402-2413.
55. Morishita R, Gibbons GH, Ellison KE, et al. Single intraluminal delivery of antisense cdc2 kinase and proliferatingcell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 1993;90:8474-8478.
56. Chang MW, Ohno T, Gorson D, et al. Adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene inhibits vascular smooth muscle cell proliferation and neointima formation following balloon angioplasty of the rat carotid artery. Mol Med 1995;1:172-181.
57. von der Leyen HE, Gibbons GH, Morishita R, et al. Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995:92:1137-1141.
58. Dichek D, Schneider DB, Newman KD. Modification of the vascular phenotype by viral gene transfer: Therapy and toxicity. J Vasc Surg 1996;24:163-165.
59. Rade JJ, Schulick AH, Dichek DA. Adenovirus-mediated delivery of hirudin to injured rat arteries reduces neointima formation (abstract). Circ 1995;92 suppl I: 1501.
60. Indolfi C, Avvedimento EV, Rapacciuolo A, et al. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nature Medicine 1995;1(6): 541-545.
61. Ludwig S, Rapp UR. Cascading towards vascular disorder gene therapy. Nature Medicine 1995;1995:513-515.
62. Billiar TR, Tzeng E, Shears LL, III. iNOS overexpression to modify disease states. J Vasc Surg 1996;24:159-160.
63. Chang MW, Barr E, Seltzer J, et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995;267:518-522.
64. Chang MW, Barr E, Lu MM, et al. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest 1995:95:2260-2268.
65. Leiden JM. Cytostatic gene transfer for vascular proliferative disorders. J Vasc Surg 1996;24:163.
66. Clowes AW. Intimal hyperplasia and graft failure. Cardiovasc Pathol 1993;2:179S-186S.
67. Cox JL, Chiasson DA, Gotlieb AI. Stranger in a strange land: The pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Prog Cardiovasc Dis 1991;1:45-68.
68. Schwartz LB, Pence JC, Kerns BJ, et al. Kinetics of experimental vein graft cell division and function. Surg Forum 1991;27:363-365.
69. Mann MJ, Gibbons GH, Kern off RS, et al. Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci USA 1995;92:4502-4506.
70. Gibbons GH, Dzau VJ. Molecular therapies for vascular diseases. Science 1996;272:689-693.
71. Umans JG, Levi R. Nitric oxide and the regulation of blood flow and arterial pressure. Annu Rev Physiol 1995;57:771-790.
72. Billiar TR. Nitric oxide: Novel biology with clinical relevance. Ann Surg 1995;221:339-349.
73. Schulick AH, Dong G, Newman KD, et al. Endotheliumspecific in vivo gene transfer. Circ Res 1995;77:475-485.
74. Podrazik RM, Whitehill TA, Ekhterae D, et al. High-level expression of recombinant human tPA in cultivated canine endothelial cells under varying conditions of retroviral gene transfer. Ann Surg 1992;216:446-453.
75. Dichek DA, Nussbaum O, Degen SJF, Anderson WF. Enhancement of the fibrinolytic activity of sheep endothelial cells by retroviral vector-mediated gene transfer. Blood 1991;77:533-541.
76. Whitehill TA, Podrazik RM, Ekhterae D, et al. Retroviralmediated human tPA gene transfer in canine endothelial cells: Comparative effects of protamine and polybrene on cellular transduction and gene expression. Surg Forum 1992;42:337-339.
77. Ekhterae D, Stanley JC. Retroviral vector-mediated transfer and expression of human tissue plasminogen activator gene in human endothelial and vascular smooth muscle cells. J Vasc Surg 1995;21:953-962.
78. Zoldhelyi P, McNatt J, Xu XM, et al. Prevention of arterial thrombosis by adenoviral-mediated transfer of cyclooxygenase gene. Circ 1996;93:10-17.
79. DeFrang RD, Taylor LM, Jr., Porter JM. Amputations. In Porter JM, Taylor LM, Jr., eds. Basic data underlying clinical decision making in vascular surgery. St. Louis: Quality Medical Publishing, Inc., 1994, pp 153-158.
80. Isner JM. Therapeutic angiogenesis: a new frontier for vascular therapy. Vasc Med 1996;1:79-87.
81. Asahara T, Bauters C, Pastore C, et al. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimai hyperplasia in ballooninjured rat carotid artery. Circ 1995;91:2793-2801.
82. Isner JM, Walsh K, Symes J, et al. Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease. Circ 1995;91:2687-2692.
83. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. New Engl J Med 1994;331:496-501.
84. Eberhart R. Genetic modification of intravascular stents. J Vasc Surg 1996;24(1):173.
85. Veith FJ, Gupta SK, Ascer E, et al. Six-year prospective multicenter randomized comparison of autologous saphenous vein and expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstructions. J Vasc Surg 1986;3: 104-114.
86. Zilla P, Deutsch M, Meinhart J, et al. Clinical in vitro endothelialization of femoropopliteal bypass grafts: An actuarial follow-up over three years. J Vasc Surg 1994;19:540-548.
87. Herring M, Smith J, Dalsing M, et al. Endothelial seeding of polytetrafluoroethylene femoral popliteal bypasses: The failure of low-density seeding to improve patency. J Vasc Surg 1994;20:650-655.
88. Huber TS, Welling TH, Sarkar R, et al. Effects of retroviralmediated tissue plasminogen activator gene transfer and expression on adherence and proliferation of canine endothelial cells seeded onto expanded polytetrafluroethylene. J Vasc Surg 1995;22:795-803.
89. Geary RL, Clowes AW, Lau S, et al. Gene transfer in baboons using prosthetic vascular grafts seeded with retrovirally transduced smooth muscle cells: A model for local and systemic gene therapy. Human Gene Therapy 1994;5: 1211-1216.
90. Stanley JC. Genetic manipulation of seeded endothelial cells in vascular prostheses. J Vasc Surg 1991;13(5):736-738.
91. Dichek DA, Anderson J, Kelly AB, et al. Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retoviral vectors. Circ 1996;93:301-309.
92. Callow AD. The vascular endothelial cell as a vehicle for gene therapy. J Vasc Surg 1990;11:793-798.
93. Newman KD, Nguyen N, Dichek DA. Quantification of vascular graft seeding by use of computer-assisted image analysis and genetically modified endothelial cells. J Vasc Surg 1991:14:140-146.
94. Clowes AW. Improving the interface between biomaterials and the blood: The gene therapy approach. Circ 1996;93: 1319-1320.
95. Takeshita S, Gal D, Leclerc G, et al. Increased gene expression after liposome-mediated arterial gene transfer associ-ated with intimai smooth muscle cell proliferation. J Clin Invest 1994;93:652-661.
96. Rome JJ, Shayani V, Flugelman MY, et al. Anatomic barriers influence the distribution of in vivo gene transfer into the arterial wall. Modeling with microscopic tracer particles and verification with a recombinant adenoviral vector. Arterioscler Thromb 1994;14:148-161.
97. Guzman RJ, Hirschowitz EA, Brody SL, et al. In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the her-pes simplex virus thymidine kinase gene. Proc Natl Acad Sci USA 1994;91:10732-10736.
98. Messina LM, Podrazik RM, Whitehill TA, et al. Adhesion and incorporation of lacZ-transduced endothelial cells into the intact capillary wall in the rat. Proc Natl Acad Sci USA 1992;89:12018-12022.
99. Messina L. Endothelial cells for systemic and local gene therapy. J Vasc Surg 1996;24(1):156-157.
100. Clowes AW. Smooth muscle cells for systemic and local therapy. J Vasc Surg 1996;24(1):158-159.